Prevention of hepatobiliary cancers
Hepatobiliary cancers represent a significant problem around the globe. The most common hepatobiliary cancers are: liver cancer, cholangiocarcinoma and gallbladder cancer. In ESCALON, we aim to better understand how these tumors behave and to find ways to diagnose them early on. Through application of new technologies we will attempt to understand if hepatobiliary cancers can be predicted and diagnosed early through blood markers.
Hepatobiliary tumors are difficult to predict and diagnose with the current standard methods. For example, liver cancer requires abdominal ultrasonography every 6 months in those at risk in order to “screen” for the tumor, so to find it at early stages. There is no accepted screening method for cholangiocarcinoma or gallbladder cancer. Moreover, diagnosis of these tumors usually requires invasive methods and complex imaging technology that is not readily available in many areas. In Latin America, these problems are exacerbated by a number of factors such as higher risk for these tumors and difficult access to specialized centers for some patients, among others.
Below an overview of all news and events related to ESCALON.
We have sent our first newsletter to all who were interested in ESCALON and its activities.Read more
Liver Cancer Summit
The next event that we will be attending is the Liver Cancer Summit- 6 to 8 February 2020 in Prague.Read more
The 1st ESCALON Symposium was held in Cordoba, Argentina on November 15, 2019.Read more
ESCALON kick-off meeting
The ESCALON in person Kick-off meeting was performed on April 9th , 2019 in Vienna.Read more
The consortium is formed by physicians, scientists, epidemiologists, statisticians and media specialists in multiple countries across Europe and South America. Each task, designed to work on a different hepatobiliary cancer, is led by a center in one continent in close collaboration with a center in a different continent (Europe and South America).
Angela Bastidas Coral
Enrique Carrera Estupiñán
Here you can find all publications related to ESCALON.
Hepatocellular carcinoma, a unique tumor with a lack of biomarkers
Debes JD, Carrera E, Mattos AZ, Prieto JE, Boonstra A; ESCALON investigators. Ann Hepatol. 2019; pii: S1665-2681(19)32214-8. doi: 10.1016/ j.aohep.2019.07.009 PMID: 31494068.Donwload PDF
Hepatobiliary cancers in South America: disparity strikes
Debes JD, Boonstra A, Balderramo D, Mattos AZ, Arrese M; ESCALON investigators. Lancet Gastroenterol Hepatol. 2019; 4:581. doi: 10.1016/S2468-1253(19)30188-8 PMID: 31292069.Donwload PDF
Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network
S Leathers J, Balderramo D, Prieto J, Diehl F, Gonzalez-Ballerga E, Ferreiro MR, Carrera E, Barreyro F, Diaz-Ferrer J, Singh D, Mattos AZ, Carrilho F, Debes JD J Clin Gastroenterol. 2019; 53:464-469. doi: 10.1097/ MCG. 0000000000001085.Donwload PDF
Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals
Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze Zur Wiesch J, von Felden J, de Knegt RJ, Boonstra A. Gastroenterology.2018;154:515-517.e3.doi:10.1053/ j.gastro.2017.10.035Donwload PDF
Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy
Debes JD, Chan AJ, Balderramo D, Kikuchi L, Gonzalez Ballerga E, Prieto JE, Tapias M, Idrovo V, Davalos MB, Cairo F, Barreyro FJ, Paredes S, Hernandez N, Avendaño K, Diaz Ferrer J, Yang JD, Carrera E, Garcia JA, Mattos AZ, Hirsch BS, Gonçalves PT, Carrilho FJ, Roberts LR Liver Int. 2018; 38:136-143. doi: 10.1111/liv.13502.Donwload PDF
Below an overview of the workpackages related to ESCALON.
We have formed a consortium that successfully established the epidemiology of liver cancer in South America involving multiple countries in the region. For this project we have expanded our network to other South American and European partners, incorporating area-specific experts and assembling a study team with unique characteristics in order to address the key needs related to hepatobiliary malignancies in the region.
Relevant patient organisations
You can find the relevant contact persons of this project below.